NGR-hTNF: Phase II started

MolMed began the open-label, Italian Phase II Study NGR016 trial to evaluate weekly IV infusions of 0.8 and 45 µg/m 2 NGR-hTNF alone and in combination with Doxil doxorubicin in 96 patients. Johnson...